Seeking Alpha


Send Message
View as an RSS Feed
View karibruce's Comments BY TICKER:
Latest  |  Highest rated
  • Spectrum Bonds That Yield Almost 5% [View article]
    Yes that is my strategy. Buy a bond at 6% over the par price and just think it won't be called. I just did a lot of research about senior notes with >6% yield, selling near par. Need these for my aging mother.
    Mar 22, 2015. 06:00 PM | Likes Like |Link to Comment
  • Omega Healthcare: Another REIT That Should Be Part Of Any Dividend Investors' Portfolio [View article]
    I don't have appetite for this investment. Ever since my mother entered independent living that institution has cut back on their services. Transportation services cut back, and the food quality has declined considerably. They are owned by a large publicly traded corporation. I will find ways to invest and get dividends without this direct impact on our senior citizens.
    Sep 18, 2014. 02:30 PM | 1 Like Like |Link to Comment
  • Has The Tekmira Pharmaceuticals Ebola Trade Run Its Course? [View article]
    Enjoying TKMR roller coaster ride. Not being flippant here, I am also concerned for those suffering from Ebola. I add, one has to wonder when TKMR will do a secondary?
    Aug 5, 2014. 01:19 PM | 1 Like Like |Link to Comment
  • Tekmira riding another company's Ebola wave [View news story]
    That's right Nick. I am so thankful that our two American patients have improved. But this is not a clinical trial, this is not even compassionate use (not officially anyway). You can not draw conclusions on two patients. Lenghthy clinical trials are tedious but absolutely necessary to have a scientific conclusion. (Remember Thalidomide. Must have adequate clinical trials before allowing public use of drugs). And there has been no biotech company willing to endure this expensive process without government funding. Now I hope the government wil continue to fund Mapp and Tekmira to determine if both treatments are successful. Certainly now there is impetus to spend the money on it. (Disclosure: Earned a little money on Tekmira trades, still holding about half my shares).
    Aug 4, 2014. 01:58 PM | Likes Like |Link to Comment
  • Spectrum Pharmaceuticals: Key Drug Fusilev May Face Generic Competition Soon [View article]
    I propose this website seek a name change, "Seeking Shorts".
    Jul 9, 2014. 07:03 PM | 7 Likes Like |Link to Comment
  • Are You Pressing Your Luck With mREITs? [View article]
    The preferred shares of mREITs are generally perpetual issues. Many are selling at less than par. How do you get rid of them without losing principle?
    Jun 4, 2014. 08:02 AM | Likes Like |Link to Comment
  • Athersys: Down But Not Out - An Interview With CEO Van Bokkelen [View article]
    Great interview. I really appreciate your effort. Next interview I want the answers to the really really tough questions. Some examples:

    1. How many patients are currently enrolled in the ischemic stroke clinical trial?

    2. Why the absence of any interim data on the ischemic stroke trial? Last press release was October 2012, announcing safety data only.

    I have been finding this to be a great speculative investment, especially since the company has no debt outstanding. They actually have shown some efficacy for their Multistem in early trials for myocardial infarction and in graft vs. host disease. I have spent some time studying this company, it's in their news releases on their website. But there has been a serious lack of any positive results over the past two years. All comments from this company is now sounding like unsubstantiated hype. I still have some shares, many with fairly low cost basis. I am so tempted to bail soon so I don't lose money.
    May 23, 2014. 11:35 AM | 1 Like Like |Link to Comment
  • Athersys: Down But Not Out - An Interview With CEO Van Bokkelen [View article]
    Hey too smart, I read your article. Yes it is a tragic situation. The treatment she got was a bone marrow transplant, which was donated by her mother. There is always a risk of graft vs. host disease with bone marrow transplant. This type of transplant has nothing to do with Athersys. Just an interesting fact, the first FDA approved stem cell product, Prochymal, is approved to treat graft vs host disease. And Athersys is going to do a phase 2 trial of Multistem to treat graft vs host disease. Yes it is complicated, all this medical jargon.
    May 23, 2014. 08:07 AM | Likes Like |Link to Comment
  • Athersys' (ATHX) CEO Gil Van Bokkelen on Q1 2014 Results - Earnings Call Transcript [View article]
    Prochymal is non-embryonic. It is FDA approved. I can not tell you whether Multistem will ever be proven effective in treating anything or not. But it is incorrect to state that non-embryonic stem cell therapies are categorically junk.
    One real problem here is that this type of research, the type being done by Athersys used to be funded by our government, by NIH. Now that we have such huge debt, NIH can no longer fund it. So it is being done by many many companies like Athersys. They get very little funding from NIH. Most of their funding is aquired, lives and dies being battered by hedge funds and venture capital, the casino of Wall Street, and every step the company takes is nitpicked by investors on sites such as this. (And sometimes there are some crumbs for the lawyers too, Galena).
    The spending in biotech and even on FDA approved medical treatments is astronomical. Women pay $3000 for gene profiling of their breast cancer to find out how effective chemotherapy might be for their personal cancer. This test seldom determines if chemo will be given or not. Yet most breast cancer patients are urged to get this expensive test before chemo is started. Same story for lung cancer, colon cancer, etc. The spending is outrageous in the hopes of offereing a better outcome for some of those patients. Athersys is in this same process, but at the developmental stage. I don't see any reason at all to single out Athersys and call "foul"
    May 13, 2014. 12:26 PM | 2 Likes Like |Link to Comment
  • Athersys' (ATHX) CEO Gil Van Bokkelen on Q1 2014 Results - Earnings Call Transcript [View article]
    I can say as a medical professional and as a family member of an ulcerative colitis patient, the statements by the officers of Athersys are medically correct. This discussion appears very transparent. I have to commend this company for attempting to jump forward parabolic ally and attempt to treat the toughest diseases. I like the analogy of putting out the raging fire versus putting out the campfire. When my mom was sick with UC, she had a raging fire in her gut that almost killed her. Surgery was the only answer. The surgery nearly killed her. If this treatment can make a difference in one area, UC, stroke, AMI or GVHD then it will be a total home run. Prochymal already shows efficacy in GVHD. Invest wisely, buy low and sell high. But at this point I don't see a reason to trash the reputation of this company, in my professional opinion. (Would love to see a company from Cleveland Ohio make history).
    May 13, 2014. 09:39 AM | 1 Like Like |Link to Comment
  • Retirement Strategy: When Should We Sell Shares? [View article]
    I started investing in 2008. Stopped blindly investing in mutual funds and took charge. Hardest decision was when to sell. Recently took small amount of my Exxon profit off the table in taxable account. For those of you concerned about taxes, I found that my brokerage lets me choose which shares to sell. I chose the "highest cost basis" shares and my capital gains were only 15% of my total. I ended up selling back many of the partial shares that I had earned from DRIPing my dividends, because the cost basis on those was higher than the shares in my initial investment. Needed some money for kids college bills.
    Apr 25, 2014. 02:00 PM | 2 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Dear Louis,

    Did you miss the dip to under $4? So did I darn it I'm busy at work. Your only hope may be covered calls. This is a risk worth taking.
    Feb 26, 2014. 11:00 AM | Likes Like |Link to Comment
  • Trade Update - Prana Biotechnology [View instapost]
    I agree with you, if Prana has even marginally good results in the Alzheimer's trial, the price should easily exceed $17 share. I am just learning options trading now. My options trading appliciation is turned in. What about this strategy. Hold my PRAN shares (several thousand in several accounts). Not worried about holding them because I have already made back my initial investment and playing with "house money". Sell covered calls for May 17 for that $17 share price. I will make money with the calls. If the shares are called away, I can buy them back in open market. Shares could dip lower after going up to $17 due to dilution or just price volatility. You know dilution is coming sometime no matter what the future data holds. I welcome comments on this strategy, since I am new to options (polite comments).
    Feb 24, 2014. 05:18 PM | Likes Like |Link to Comment
  • GALE: The Oncologist's Perspective On A Life Saving Therapy [View instapost]
    As a medical professional, I also applaud this article as balanced presentation of the facts to date. The clinical trail data to date are amazingly compelling. Can the data in Ph 3 come close to this? We don't know. Have seen several biotechs with terrific PH 2 data, but htey crash and burn on larger PH 3 trail (example ONTY). Then the beautiful thing here for an investor is to buy on dips in price and sell when it goes up. Recoup your initial investment, then you can hold shares as long as it takes, or as long as you are comfortable. My guess for near term is more price pressure as law firms pursue this company. I am comfortable considering further investing moves in and out of this stock.
    Is there greed and corruption going on here with the company and/or various authors? Yes I'm sure there is. Does that impact the scientific results? Only if the results to date have been fudged. This also has happened with other companies, but I am not accusing Galena of that.
    For long term, I really hope this treatment is successful. Twenty years ago I was looking at the Her2 marker on breast cancer cells in laboratory, before current treatments were developed. Was sad that so many of those patients died. We need this treatment since only about 15 to 20% of breast cancer patients are Her2 3+, and eligible for treatment with Herceptin, etc.
    Feb 15, 2014. 01:37 PM | 4 Likes Like |Link to Comment
  • A Deeper Look At The Galena Biopharma Controversy [View article]
    I have a list of authors I follow on Seeking Alpha. I wish this website would make it possible to keep another list of authors - those who we don't believe or suspect of writing pump and dump articles. Seriously, I am having a hard time sorting them out.

    I also wish Seeking Alpha would be transparent with us about articles that are removed. Alert us if we have read those articles or those authors.
    Feb 15, 2014. 12:00 AM | 2 Likes Like |Link to Comment